Aim of this review is to propose an acceptable surgical indication for conversion surgery in patients with initially unresectable (UR) pancreatic ductal adenocarcinoma (PDAC) by considering desirable outcomes, including resectability, overall survival (OS), and disease-free survival (DFS). A comprehensive literature search of PubMed was conducted through July 15, 2019. Eligible studies were those reporting on patients with UR-PDAC who underwent surgery. We excluded case reports with fewer than 10 patients, insufficient descriptions of survival data, and palliative surgery.
| INTRODUC TI ON
Pancreatic ductal adenocarcinoma (PDAC) continues to have a dismal prognosis with a 5-year survival rate of <5%, even in the modern era. 1, 2 Most (70%-80%) patients with PDAC have unresectable (UR) disease, which is subclassified according to the status of distant metastasis-locally advanced disease (UR-LA) and metastatic disease (UR-M), such as distant organ metastasis and non-regional lymph node metastasis. Recent implementation of new regimens, such as FOLFIRINOX 3 and gemcitabine + nab-paclitaxel, 4 has provided better clinical response rates, ranging from 23% to 31.6%, and median survival time (MST), ranging from 8.5 to 12 months, even in patients with metastatic PDAC. Recently, conversion surgery, an additional surgery during multimodal therapy in patients with initial UR-PDAC, has been introduced with the goal of prolonging short-and long-term survival. Number of publications on conversion surgery has increased in recent years. Several review articles [31] [32] [33] [34] [35] [36] have reported high resectability rates, high margin-negative resection rates, and high negative lymph node rates in patients who underwent conversion surgery with acceptable mortality and morbidity. MST in patients with initial UR-PDAC who underwent conversion surgery was better than that of patients who did not undergo conversion surgery. However, most publications have described unclear surgical indications and varying rates of resectability, overall survival (OS), and disease-free survival (DFS). As evidence-based guidelines for the management of UR-PDAC are lacking, this review aims to propose an optimal surgical indication considering desirable outcomes of conversion surgery, with special consideration to resectability, OS, and early recurrence rate.
| ME THODS

| Search strategy and data sources
Identification of eligible studies was carried out through a search of PubMed (MEDLINE) through 15 July 2019. The following search terms were used: "(unresectable pancreatic ductal adenocarcinoma OR unresectable pancreatic cancer) AND (pancreatectomy OR surgical resection)". Finally, the reference lists of eligible studies were assessed manually to detect any potentially relevant articles ("snowball" procedure).
| Inclusion and exclusion criteria
Eligible studies were those reporting on patients with histologically confirmed unresectable PDAC who underwent surgery after multimodal therapy, including chemotherapy/radiation therapy. Exclusion criteria were as follows: (i) irrelevant studies, (ii) editorials and letters to the editor, (iii) non-English articles, (iv) case reports including fewer than 10 patients undergoing surgical resection, (v) insufficient description of survival data, and (vi) studies involving treatment mainly by ablative or non-surgical technologies.
| Data extraction and tabulation
Two authors (S.S. and T.Y.) conducted data extraction. Variables of interest included general study characteristics (eg, study period, study design, number of patients, resectability), regimens of multimodal therapy and percentages of patients who received them, surgical indication, OS and DFS, and predictive factors for surgical outcome. Data were tabulated when possible. Discordant judgment was resolved by discussion and consensus.
| RE SULTS
| Article selection and study demographics
Following the initial algorithm and the successive steps of the selection process, including screening of the titles and abstracts, six review articles [31] [32] [33] [34] [35] [36] and 26 original articles, including two phase II studies and one prospective cohort study, were selected for this review. Finally, 26 articles reported surgical outcomes after conversion surgery (Table 1) . Seventeen articles showed a surgical indication for conversion surgery in patients with initial UR-PDAC. 10, 11, 13, 15, 17, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Fifteen articles 7, 9, 10, [12] [13] [14] 16, 18, 19, [22] [23] [24] [25] [26] 30 were abstracted for investigation of predictive factors for resectability, OS and DFS.
| Outcomes of conversion surgery
Several articles reported that conversion surgery could be carried out safely despite a high incidence of portal vein or arterial resection, ranging from 8% to 81%. Mortality and morbidity ranged from 0% to 7% and from 14% to 89%, respectively. Several studies showed high resectability rates (UR-LA, 20% to 69%; [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] UR-LA/M, 4.1% to 61%; [18] [19] [20] [21] [22] [23] [24] [25] UR-M, 2% to 43% [26] [27] [28] [29] [30] ), high margin-negative resection rates (UR-LA, 55% to 89%; UR-LA/M, 27% to 89%; UR-M, 51% to 91%), and high negative lymph node rates (UR-LA, 38% to 83%; UR-LA/M, 29% to 89%; UR-M, 50% to 63%) in patients who underwent conversion surgery. MST in patients with initial UR-LA, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] with LA/M, [18] [19] [20] [21] [22] [23] [24] [25] and with M 26-30 ranged from 24.9 to >40 months, 19.5-64 months, and 21.9-56 months, respectively.
Although surgical indication and resectability varied, MST did not seem to vary according to resectability status.
| Surgical indication for and resectability of conversion surgery
Seventeen articles reported a surgical indication for conversion surgery in patients with initial UR-PDAC. 10, 11, 13, 15, 17, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] 
| Predictive factors for resectability and overall survival
| Resectability
Five articles identified prognostic factors for resectability in patients with initial UR-PDAC. 7, 12, 13, 23, 30 Four of them found that decreased CA19-9 level was a predictor of resectability. 7 
| Overall survival and disease-free survival
Eleven articles reported prognostic factors for OS in patients with initial UR-PDAC. 9, 10, 14, 16, 18, 19, 22, [24] [25] [26] 30 Eight of them found that decreased CA19-9 level was a prognostic factor for OS. 10, 16, 19, 22, [24] [25] [26] 30 Three articles found that CA19-9 response was a prognostic factor for PFS. 14, 16, 25 Reni et al 10 Two of five articles [26] [27] [28] [29] [30] 
| D ISCUSS I ON
On imaging studies, the majority of PDAC is classified as UR disease. Conversion surgery provided favorable outcomes of a high proportion of margin-negative resection and negative lymph node metastasis, resulting in improved MST ranging from 19.5 to 64 months in patients with initial UR-PDAC. 7, 9, 10, [12] [13] [14] 16, 18, 19, [22] [23] [24] [25] [26] 30 When patients were selected after a favorable response to anticancer treatment followed by conversion surgery, MST did not seem to differ accord- to 61% in UR-LA/M in two 19, 22 of eight articles, [18] [19] [20] [21] [22] [23] [24] [25] and 2%-43% in UR-M in three 27, 29, 30 of five articles. [26] [27] [28] [29] [30] Rates of resectability after FOLFIRINOX seemed to be higher relative to other regimens.
In the present review, the surgical indication for conversion surgery remains unclear, and it differed in each institution. One institution had strict criteria, as follows: tumor shrinkage to R/BR status, decreased levels of tumor marker, maintenance of performance status, and a long interval between initial treatment and surgical resection. 11, 20, 21, 24, 28 decreased CA19-9 level was a predictor. 7, 13, 23, 30 Eight of 11 articles identifying predictors of OS also showed decreased CA19-9 level as a prognostic factor for OS. 10, 16, 19, 22, [24] [25] [26] 30 All three articles reporting prognostic factors for DFS showed that CA19-9 response was a prognostic factor. 14, 16, 25 Among them, the Heidelberg group clearly showed that a post-chemotherapy CA19-9 level <100 U/mL was a favorable prognostic factor for OS and a post-chemotherapy CA19-9
level ≧100 U/mL was a predictor of poor DFS in 280 patients with initial UR-PDAC, including BR in 6%, UR-LA in 68%, and UR-M (oligometastasis) in 26%. 25 They also showed that a post-chemotherapy CA19-9 level <150 U/mL was a favorable prognostic factor for OS as well as DFS in 101 patients with UR-M undergoing exploratory surgery (43 patients resected). 30 In contrast, Rangelova et al 17 reported that for all preoperative values of CA19-9, surgical resection had a positive impact on survival. They concluded that all patients with BR/LA-PDAC who did not progress during multimodal therapy should be considered for surgical resection, irrespective of the type or dose of regimen given. Higher levels of CA19-9 should not be considered an absolute contraindication for resection. 17 Although it is still controversial, several articles reported that a decreased CA19-9 level after multimodal therapy was a reliable predictive factor for resectability, OS, and DFS. 7, 10, 13, 14, 16, 19, [22] [23] [24] [25] [26] 30 Tsai et al also suggested that a decrease in CA19-9 level following systemic therapy was a useful marker for treatment success, even in patients with localized PDAC. 38 Thus, decision-making for conversion surgery based on clinical response defined by RECIST and decreased CA19-9 level after multimodal therapy may be appropriate.
When patients with initial UR-PDAC experience significant tumor shrinkage (complete or partial response) to R/BR status, decision-making for conversion surgery is easy. However, decisions are still controversial in patients showing stable disease after multimodal therapy, because it is difficult to differentiate whether viable tumor tissue is present on contrast-enhanced CT imaging. 16, 19 In these situations, CA19-9 level <100 U/mL or 150 U/mL in UR-PDAC can be a reliable marker for conversion surgery (Figure 1 ). Moreover, use of diffusion-weighted magnetic resonance imaging (MRI) 39 
| Desirable outcomes for conversion surgery and future perspectives
Recent chemotherapy regimens, such as FOLFIRINOX and gem + nab-PTX, provide better MST of 24.2 months in UR-LA 37 and 8.5-12 months in UR-M. 3, 4 Although conversion surgery is expected to prolong survival, we should definitely recognize that the early recurrence rate (within 6 months) after conversion surgery is approximately 30%. 14, 16, 25 In this situation, patients cannot expect a longer survival relative to non-surgical patients, and conversion surgery may simply be a surgical injury for patients, because extensive pancreatectomy has a high risk of mortality and morbidity. 36 The early recurrence rate should be decreased as much as possible in patients who undergo conversion surgery. From the prognostic point of view, desirable outcomes of an MST of 36 months in patients with UR-LA and 24 months in patients with UR-M and less than a 20% incidence of early recurrence after conversion surgery, but not high resectability, may be required for obtaining a survival benefit in the modern era. Therefore, the surgical indication for conversion surgery should be carefully decided in a multidisciplinary meeting and should be relatively limited according to radiological findings as well as the CA19-9 level. van Veldhuisen et al 31 have suggested that in addition to CA19-9, other promising biomarkers, such as micro-RNAs and circulating tumor DNA, may more accurately predict treatment response in UR-PDAC. [41] [42] [43] In the near future, reliable surrogate markers for predicting resectability, early recurrence, and favorable prognosis should be explored.
Moreover, the optimal timing between initial treatment and surgical resection, an accurate method to evaluate tumor remission, and the type/duration of multimodal therapy are still under investigation.
Several prospective studies are now in progress. 35, 36 Sustainable efforts will be required to prolong survival in patients with UR-PDAC.
| CON CLUS ION
Number of candidates for conversion surgery is now increasing
with the introduction of modern chemotherapy regimens; however, the actual clinical benefits of resection have not yet been fully investigated. Although conversion surgery can improve longterm survival in patients with UR-PDAC, the early recurrence rate should be recognized. There are still several problems to be resolved in this area, and prospective studies will be needed to explore the clinical benefit of conversion surgery. An appropriate surgical indication for achieving desirable outcomes can definitely provide further improved survival and early recurrence rates.
Therefore, novel biomarkers predicting resectability, OS and DFS should be investigated in the near future.
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